New drug SRG-514 tested during breast cancer surgery

NCT ID NCT06300411

Ongoing Disease control Sponsor: SURGE Therapeutics Source: ClinicalTrials.gov ↗

First seen Feb 23, 2026 · Last updated May 20, 2026 · Updated 15 times

Summary

This early-phase trial tests a new drug called SRG-514, which is applied directly to the tumor site during breast-conserving surgery. The goal is to find the safest dose and see how the body handles it. About 24 adults with breast cancer are taking part. This study focuses on safety and dosing, not on curing the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Audie Murphy VA

San Antonio, Texas, 78229, United States
Duke Cancer Center

Durham, North Carolina, 27710, United States
Indiana University

Indianapolis, Indiana, 46202, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Mayo

Rochester, Minnesota, 55905, United States
Memorial Health

Savannah, Georgia, 31404, United States
NYU Langone Health

New York, New York, 10016, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

BREAST CANCER